OPS 172
Alternative Names: Ang 1-7; Angiotensin-(1-7); OPS-172Latest Information Update: 26 Sep 2022
At a glance
- Originator Stanford University
- Developer Ocean Promise
- Class Anti-inflammatories; Antivirals; Small molecules
- Mechanism of Action Proto-oncogene protein c-mas-1 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 30 Jun 2022 Ocean Biomedical plans a phase I/II clinical trial in COVID-2019 infections in USA (IV) in second half of 2022 (NCT04570501)
- 08 Apr 2022 Ocean Biomedical plans a phase I/II trial in COVID-2019 infection (Adjunctive therapy) is second half of 2022
- 03 Mar 2022 Stanford University withdraws its phase I/II trial in COVID-2019 infections in USA (IV, infusion) before enrolment (NCT04570501)